Sleep Supplements: the category consumers are evaluating

The only authorized claim covers half of the category

Melatonin is the only ingredient in this category with sleep-related indications authorized in Europe. Regulation (EU) No . 432/2012 authorizes two such indications. The first concerns jet lag and is achieved with a minimum dose of 0.5 mg, taken shortly before bedtime on the first day of travel and for a few days after arrival. The second claim underpins the entire category: Melatonin helps reduce the time it takes to fall asleep, provided that the product contains 1 mg per serving and that consumers are informed that the effect is achieved by taking that milligram shortly before bedtime.

It’s worth looking at how we got here, because it explains a lot. The Member States had submitted three effects for evaluation: regulation of the sleep-wake cycle, relaxation, and sleep rhythms. The EFSA panel recognized a cause-and-effect relationship for only one of these—the reduction in sleep latency—and based the entire indication on that finding.

The claim is about how long it takes you to fall asleep—not how well you sleep afterward. And the market is shifting precisely where the official rhetoric doesn’t reach.

This is the crux of the matter for anyone developing a sleep product today. When it comes to falling asleep, there is a well-established claim, a defined dosage, and a broad target population. When it comes to sleep quality—which is the direction in which demand is shifting—support for labeling claims must be sought in botanicals traditionally associated with rest, whose indications remain under the European transitional regime and, in Italy, follow the wording specified in the decree on botanicals. This is not a shortcut; it is a narrower and more cautious framework than what marketing would gladly employ.

In Italy, the claim amount also serves as the cap

There is also a quantity restriction that applies only to the Italian market, and this is the least well-known aspect of the matter. In Note No . 0027074 dated June 24, 2013, the Ministry of Health reassessed the permitted levels of Melatonin in dietary supplements, noting that the milligram required to support the authorized claim should also be considered the maximum permissible intake for physiological purposes. The reason is one of demarcation: on the European market, there are authorized Melatonin-based medicines with daily dosages of 2 mg, and a clear distinction was needed between supporting a bodily function and a therapeutic effect.

The formulation range for this ingredient is a single value, not a range: below 1 milligram, the claim is lost; above it, the product falls outside the category.

The claim is European, but the dose is not

For those looking at foreign markets, this raises a distinction that extends far beyond Melatonin. The claim is harmonized: the same statement, under the same conditions, applies in all twenty-seven Member States. The maximum levels of use for substances other than vitamins and minerals, however, are not harmonized and remain a matter of national jurisdiction. The same product, with the same label, can therefore be fully compliant in one country and non-compliant in another. This is a check that must be performed before finalizing the formula, not after the packaging has been printed.

Side ingredients do not carry the claim

Finally, there is the most common mistake, which concerns the supporting ingredients. Magnesium has authorized claims regarding the normal functioning of the nervous system and normal psychological function, not sleep. Including it in a formula is legitimate and can be substantiated; using it to make a claim about sleep is not. The same reasoning applies to adaptogens used for stress relief, including Ashwagandha: the ingredient’s role in the formula is one thing; the claim on the label is another.

The segments that no on, or almost no one, serves

The category is crowded around the average consumer but virtually empty everywhere else. Here are three concrete examples.

First and foremost, shift workers: those who work at night have a structural—not just occasional—sleep problem and a need for reversed schedules that no mainstream product takes into account. A British startup has just built its initial market positioning around this, which shows just how much uncharted territory this was.

Then there is the female hormonal transition, during which sleep disturbances are among the most commonly reported symptoms and often among the first to appear: this is an area we’ve already addressed when discussing Menopause and Nutraceuticals, and sleep is one of the natural entry points to this topic.

Finally, in sports, rest is just as much a part of recovery as post-workout nutrition, but it is rarely treated as such when designing training programs.

Why format matters more than usual in the evening

A sleep aid is taken at a specific time, often with the lights off, when no one feels like measuring, counting, or dissolving it. It’s the most challenging usage scenario imaginable, and the product’s format must accommodate it.

Hence the shift toward single-dose liquid packaging: the dose is fixed—no measuring, no mistakes—and it takes just one step. For an ingredient with a precise claim threshold, this advantage goes beyond mere convenience. This also explains the packaging designed around a cycle: thirty doses equal thirty evenings, making adherence clear to the consumer and predictable for the manufacturer. The same considerations that apply to the Bioavailability of an active ingredient apply, in this case, to its actual intake: an effective product that you stop taking after ten days produces no results.

Then there’s the issue of who manufactures the product. Melatonin is sensitive to light, and it’s not the only active ingredient that degrades before its stated expiration date if the packaging doesn’t protect it. In the next article, we’ll look at what it means, in practice, to choose barrier packaging.

If you’re considering a sleep-related product and would like to discuss dosages, form, and format with us, please let us know.